Re-Routing Infliximab Therapy: Subcutaneous Infliximab Opens a Path Towards Greater Convenience and Clinical Benefit.
Journal
Clinical drug investigation
ISSN: 1179-1918
Titre abrégé: Clin Drug Investig
Pays: New Zealand
ID NLM: 9504817
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
accepted:
01
05
2022
pubmed:
4
6
2022
medline:
15
6
2022
entrez:
3
6
2022
Statut:
ppublish
Résumé
Subcutaneous infliximab recently received approval for the treatment of various immune-mediated inflammatory diseases in Europe, following pivotal clinical trials in patients with rheumatoid arthritis and inflammatory bowel disease. Subcutaneous infliximab demonstrated an improved pharmacokinetic profile compared with intravenous infliximab: the more stable exposure and increased systemic drug concentrations mean it has been cited as a biobetter. Alongside the pharmacokinetic advantages, potential benefits for efficacy, immunogenicity, and health-related quality-of-life outcomes have been suggested with subcutaneous infliximab. During the coronavirus disease 2019 pandemic, the benefits of subcutaneous over intravenous therapies became apparent: switching from intravenous to subcutaneous infliximab reduced the hospital visit-related healthcare resource burden and potential viral transmission. Clinical advantages observed in pivotal trials are also being seen in the real world. Accumulating experience from four European countries (the UK, Spain, France, and Germany) in patients with rheumatic diseases and inflammatory bowel disease supports clinical trial findings that subcutaneous infliximab is well tolerated, increases serum drug concentrations, and offers maintained or improved efficacy outcomes for patients switching from intravenous infliximab. Initial evidence is emerging with subcutaneous infliximab treatment after intravenous infliximab failure. High patient satisfaction and pharmacoeconomic benefits have also been reported with subcutaneous infliximab. Treatments aligned with patient preferences for the flexibility and convenience of at-home subcutaneous administration could boost adherence and treatment outcomes. Altogether, findings suggest that switching from intravenous to subcutaneous infliximab could be advantageous, and healthcare professionals should be prepared to discuss supporting data as part of shared decision making during patient consultations. The tumor necrosis factor inhibitor infliximab is one treatment option that may be appropriate for patients with immune-mediated inflammatory diseases. Patients may prefer tumor necrosis factor inhibitors administered via the subcutaneous (SC) or intravenous (IV) route, with preferences influencing treatment satisfaction and outcomes. In 2019, CT-P13 SC became the first SC infliximab product to receive regulatory approval in Europe, based on pivotal clinical studies that compared SC infliximab to IV infliximab in patients with rheumatoid arthritis and inflammatory bowel disease. Subcutaneous infliximab is now approved in Europe for the treatment of adults with rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and psoriasis. Patients began to switch from IV to SC infliximab outside clinical trials in March 2020, during the coronavirus disease 2019 pandemic. Switching from IV to SC infliximab allowed patients to self-administer treatment at home rather than attend hospital for infusions, reducing potential hospital-acquired infections and lessening the strain on healthcare systems during the pandemic. Clinical trial evidence and growing real-world experience demonstrate that SC infliximab offers clinical advantages in terms of an improved pharmacokinetic profile and potential efficacy, immunogenicity, and health-related quality-of-life benefits compared with IV infliximab. Patients have also reported increased satisfaction with SC infliximab after switching from IV infliximab. Together with the long-standing flexibility and convenience benefits of SC administration, the clinical advantages of SC infliximab make it a valid therapeutic option for rheumatoid arthritis and inflammatory bowel disease. This warrants discussion with appropriate patients as part of shared treatment decision making.
Autres résumés
Type: plain-language-summary
(eng)
The tumor necrosis factor inhibitor infliximab is one treatment option that may be appropriate for patients with immune-mediated inflammatory diseases. Patients may prefer tumor necrosis factor inhibitors administered via the subcutaneous (SC) or intravenous (IV) route, with preferences influencing treatment satisfaction and outcomes. In 2019, CT-P13 SC became the first SC infliximab product to receive regulatory approval in Europe, based on pivotal clinical studies that compared SC infliximab to IV infliximab in patients with rheumatoid arthritis and inflammatory bowel disease. Subcutaneous infliximab is now approved in Europe for the treatment of adults with rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and psoriasis. Patients began to switch from IV to SC infliximab outside clinical trials in March 2020, during the coronavirus disease 2019 pandemic. Switching from IV to SC infliximab allowed patients to self-administer treatment at home rather than attend hospital for infusions, reducing potential hospital-acquired infections and lessening the strain on healthcare systems during the pandemic. Clinical trial evidence and growing real-world experience demonstrate that SC infliximab offers clinical advantages in terms of an improved pharmacokinetic profile and potential efficacy, immunogenicity, and health-related quality-of-life benefits compared with IV infliximab. Patients have also reported increased satisfaction with SC infliximab after switching from IV infliximab. Together with the long-standing flexibility and convenience benefits of SC administration, the clinical advantages of SC infliximab make it a valid therapeutic option for rheumatoid arthritis and inflammatory bowel disease. This warrants discussion with appropriate patients as part of shared treatment decision making.
Identifiants
pubmed: 35657560
doi: 10.1007/s40261-022-01162-6
pii: 10.1007/s40261-022-01162-6
doi:
Substances chimiques
Antibodies, Monoclonal
0
Biosimilar Pharmaceuticals
0
Infliximab
B72HH48FLU
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
477-489Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
European Medicines Agency. Remsima: summary of opinion (post authorisation). 2019. https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-remsima-x-62_en.pdf . Accessed 11 Apr 2022.
European Medicines Agency. Remsima: summary of opinion (post authorisation). 2020. https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-remsima-ii/82_en.pdf . Accessed 11 Apr 2022.
Westhovens R, Wiland P, Zawadzki M, et al. Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I/III trial. Rheumatology (Oxford). 2021;60(5):2277–87.
doi: 10.1093/rheumatology/keaa580
Schreiber S, Ben-Horin S, Leszczyszyn J, et al. Randomized controlled trial: subcutaneous vs intravenous infliximab CT-P13 maintenance in inflammatory bowel disease. Gastroenterology. 2021;160(7):2340–53.
pubmed: 33676969
doi: 10.1053/j.gastro.2021.02.068
Verma AM, Patel A, Subramanian S, et al. From intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: a pandemic-driven initiative. Lancet Gastroenterol Hepatol. 2021;6(2):88–9.
pubmed: 33444534
doi: 10.1016/S2468-1253(20)30392-7
Verma AM, Patel A. Switching from intravenous to subcutaneous infliximab biosimilar (Remsima
Argüelles-Arias F, Fernández Álvarez P, Castro Laria L, et al. Switch to infliximab subcutaneous during SARS-CoV-2 pandemic: preliminary results. Rev Esp Enferm Dig. 2022;114(2):118–9.
pubmed: 34517718
Caron B, Fumery M, Netter P, et al. Letter: treatment with subcutaneous CT-P13 in Crohn’s disease patients with intravenous infliximab failure. Aliment Pharmacol Ther. 2022;55(4):508–9.
pubmed: 35092046
doi: 10.1111/apt.16770
Baraliakos X, Tsiami S, Vijayan S, et al. Real-world evidence for subcutaneous infliximab (CT-P13 SC) treatment in patients with psoriatic arthritis during the coronavirus 2 disease (COVID-19) pandemic: a case series. Clin Case Rep. 2022;10(1): e05205.
pubmed: 35079380
pmcid: 8777045
doi: 10.1002/ccr3.5205
Alten R. Benefits of switching from IV to SC infliximab. Presented during the 'Management of rheumatic diseases during the COVID-19 pandemic' (Celltrion Healthcare) satellite symposium at EULAR Congress 2021. 2021. https://congress.eular.org/myUploadData/files/industry_programme_and_exhibitors_booklet.pdf . Accessed 11 Apr 2022.
Vijayan S, Hwangbo K, Barkham N. Real-world evidence for subcutaneous infliximab (CT-P13 SC) treatment in patients with ankylosing spondylitis during the coronavirus disease (COVID-19) pandemic: a case series. Clin Case Rep. 2022;10(1): e05233.
pubmed: 35059197
pmcid: 8757239
doi: 10.1002/ccr3.5233
McGoran J, Wilson A, McErlain S, et al. Initiation of subcutaneous infliximab (Remsima) therapy for the treatment of inflammatory bowel disease during the COVID-19 pandemic. Frontline Gastroenterol. 2022;13(1):89.
pubmed: 34966537
doi: 10.1136/flgastro-2020-101760
Buisson A, Nachury M, Reymond M, et al. Evolution of clinical and pharmacological parameters after switching from intra-venous to subcutaneous infliximab in patients with inflammatory bowel disease: the REMSWITCH study [abstract P400, presented at the 17th Congress of ECCO]. 2022. https://www.ecco-ibd.eu/publications/congress-abstracts/item/p400-evolution-of-clinical-and-pharmacological-parameters-after-switching-from-intra-venous-to-subcutaneous-infliximab-in-patients-with-inflammatory-bowel-disease-the-remswitch-study.html . Accessed 11 Apr 2022.
Chivato Martín Falquina I, Saiz Chumillas RM, Arias Garcia L, et al. Switching from an intensified regimen of infliximab to a subcutaneous standard dose in adults with inflammatory bowel disease: our experience in a tertiary hospital [abstract P617, presented at the 17th Congress of ECCO] 2022. https://www.ecco-ibd.eu/publications/congress-abstracts/item/p617-switching-from-an-intensified-regimen-of-infliximab-to-a-subcutaneous-standard-dose-in-adults-with-inflammatory-bowel-disease-our-experience-in-a-tertiary-hospital.html . Accessed 11 Apr 2022.
Smith PJ, Critchley L, Storey D, et al. Efficacy and safety of elective switching from intravenous to subcutaneous infliximab (CT-P13): a multi-centre cohort study. J Crohns Colitis. 2022. https://doi.org/10.1093/ecco-jcc/jjac053 .
doi: 10.1093/ecco-jcc/jjac053
pubmed: 35390141
Williams EL, Edwards CJ. Patient preferences in choosing anti-TNF therapies-R1. Rheumatology. 2006;45(12):1575–6.
pubmed: 17085468
doi: 10.1093/rheumatology/kel369
Lhussier M, Eaton S, Forster N, et al. Care planning for long-term conditions: a concept mapping. Health Expect. 2015;18(5):605–24.
pubmed: 23565881
doi: 10.1111/hex.12063
Kapasi R, Glatter J, Lamb CA, et al. Consensus standards of healthcare for adults and children with inflammatory bowel disease in the UK. Frontline Gastroenterol. 2020;11(3):178–87.
pubmed: 32419908
doi: 10.1136/flgastro-2019-101260
Nikiphorou E, Santos EJF, Marques A, et al. 2021 EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis. Ann Rheum Dis. 2021;80(10):1278–85.
pubmed: 33962964
doi: 10.1136/annrheumdis-2021-220249
Smolen JS, Landewe RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685–99.
pubmed: 31969328
doi: 10.1136/annrheumdis-2019-216655
Zangi HA, Ndosi M, Adams J, et al. EULAR recommendations for patient education for people with inflammatory arthritis. Ann Rheum Dis. 2015;74(6):954.
pubmed: 25735643
doi: 10.1136/annrheumdis-2014-206807
Feeney M, Chur-Hansen A, Mikocka-Walus A. People living with inflammatory bowel disease want multidisciplinary healthcare: a qualitative content analysis. J Clin Psychol Med Settings. 2021. https://doi.org/10.1007/s10880-021-09801-4 .
doi: 10.1007/s10880-021-09801-4
pubmed: 34185254
Kelly A, Tymms K, Tunnicliffe DJ, et al. Patients’ attitudes and experiences of disease-modifying antirheumatic drugs in rheumatoid arthritis and spondyloarthritis: a qualitative synthesis. Arthritis Care Res (Hoboken). 2018;70(4):525–32.
pubmed: 28732151
pmcid: 5901029
doi: 10.1002/acr.23329
Barton JL. Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy. Patient Prefer Adherence. 2009;3:335–44.
pubmed: 20016797
pmcid: 2792871
doi: 10.2147/PPA.S5835
Edel Y, Sagy I, Pokroy-Shapira E, et al. A cross-sectional survey on the preference of patients with rheumatoid arthritis for route of administration of disease-modifying anti-rheumatic drugs: oral target-specific versus parenteral biologic. Isr Med Assoc J. 2020;22(3):154–9.
pubmed: 32147979
Stoner KL, Harder H, Fallowfield LJ, et al. Intravenous versus subcutaneous drug administration. Which do patients prefer? A systematic review. Patient. 2015;8:145–53.
doi: 10.1007/s40271-014-0075-y
Bolge SC, Goren A, Brown D, et al. Openness to and preference for attributes of biologic therapy prior to initiation among patients with rheumatoid arthritis: patient and rheumatologist perspectives and implications for decision making. Patient Prefer Adherence. 2016;10:1079–90.
pubmed: 27390518
pmcid: 4913989
Solitano V, Vuitton L, Peyrin-Biroulet L, et al. The evolution of biologics administration from intravenous to subcutaneous: treatments for inflammatory bowel disease go home. Gastroenterology. 2021;160(7):2244–7.
pubmed: 33773995
doi: 10.1053/j.gastro.2021.03.038
Scarpato S, Antivalle M, Favalli EG, et al. Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis: results from a questionnaire survey (RIVIERA study). Rheumatology (Oxford). 2010;49(2):289–94.
doi: 10.1093/rheumatology/kep354
De Mits S, Lenaerts J, Vander Cruyssen B, et al. A nationwide survey on patient’s versus physician´s evaluation of biological therapy in rheumatoid arthritis in relation to disease activity and route of administration: the Be-Raise study. PLoS ONE. 2016;11(11): e0166607.
pubmed: 27893771
pmcid: 5125609
doi: 10.1371/journal.pone.0166607
Huynh TK, Ostergaard A, Egsmose C, et al. Preferences of patients and health professionals for route and frequency of administration of biologic agents in the treatment of rheumatoid arthritis. Patient Prefer Adherence. 2014;8:93–9.
pubmed: 24470758
pmcid: 3901737
Sylwestrzak G, Liu J, Stephenson JJ, et al. Considering patient preferences when selecting anti-tumor necrosis factor therapeutic options. Am Health Drug Benefits. 2014;7(2):71–81.
pubmed: 24991392
pmcid: 4049117
Sumpton D, Kelly A, Craig JC, et al. Preferences for biologic treatment in patients with psoriatic arthritis: a discrete choice experiment. Arthritis Care Res. 2021. https://doi.org/10.1002/acr.24782 .
doi: 10.1002/acr.24782
Sarzi-Puttini P, Cortesi P, Sinigaglia L, et al. THU0634 Comparing preferences of patients with rheumatic diseases, of rheumatologists, nurses and pharmacists toward the treatment of rheumatic diseases with biological agents: results from the cara study. Ann Rheum Dis. 2017;76(Suppl. 2):445.
Buisson A, Seigne A-L, D’Huart M-C, et al. The extra burden of infliximab infusions in inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(11):2464–7.
pubmed: 23942563
doi: 10.1097/MIB.0b013e3182a19268
Asnong K, Hoefkens E, Lembrechts N, et al. PREVIEW study: factors associated with willingness to switch from intravenous to subcutaneous formulations of CT-P13 and vedolizumab in patients with inflammatory bowel disease [abstract and poster N02, presented at the 16th Congress of ECCO]. 2021. https://www.ecco-ibd.eu/publications/congress-abstracts/item/n02-preview-study-factors-associated-with-willingness-to-switch-from-intravenous-to-subcutaneous-formulations-of-ct-p13-and-vedolizumab-in-patients-with-inflammatory-bowel-disease.html . Accessed 11 Apr 2022.
Vavricka SR, Bentele N, Scharl M, et al. Systematic assessment of factors influencing preferences of Crohn’s disease patients in selecting an anti-tumor necrosis factor agent (CHOOSE TNF TRIAL). Inflamm Bowel Dis. 2012;18(8):1523–30.
pubmed: 21987429
doi: 10.1002/ibd.21888
Fiorino G, Bent-Ennakhil N, Varriale P, et al. Results from a large survey exploring patient preferences for treatment attributes in inflammatory bowel disease across 7 countries in Europe [abstract P0452, presented at UEG Week 2021]. 2021. https://programme.ueg.eu/week2021/#/details/presentations/1148 . Accessed 11 Apr 2022.
Schubert S, Picker N, Wilke T, et al. Patient preferences regarding treatment with advanced therapies in ulcerative colitis: a discrete-choice experiment [abstract P0486, presented at UEG Week 2021]. 2021. https://programme.ueg.eu/week2021/#/details/presentations/1639 . Accessed 11 Apr 2022.
Chilton F, Collett RA. Treatment choices, preferences and decision-making by patients with rheumatoid arthritis. Musculoskelet Care. 2008;6(1):1–14.
doi: 10.1002/msc.110
Schreiber S, Ben-Horin S, Alten R, et al. Perspectives on subcutaneous infliximab for rheumatic diseases and inflammatory bowel disease: before, during, and after the COVID-19 era. Adv Ther. 2022;39(6):2342–64.
pubmed: 34988877
pmcid: 8731678
doi: 10.1007/s12325-021-01990-6
European Medicines Agency. Remsima: summary of product characteristics. 2022. https://www.ema.europa.eu/en/documents/product-information/remsima-epar-product-information_en.pdf . Accessed 11 Apr 2022.
Ferrante M, Sabino J, Lobaton T, et al. Introduction of subcutaneous infliximab CT-P13 and vedolizumab in daily clinical practice: outstanding questions demonstrate the need for post-marketing studies [abstract and poster P280, presented at the 16th Congress of ECCO]. 2021. https://www.ecco-ibd.eu/publications/congress-abstracts/item/p280-introduction-of-subcutaneous-infliximab-ct-p13-and-vedolizumab-in-daily-clinical-practice-outstanding-questions-demonstrate-the-need-for-post-marketing-studies.html . Accessed 11 Apr 2022.
Kim H, Alten R, Cummings F, et al. Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters. MAbs. 2021;13(1):1868078.
pubmed: 33557682
pmcid: 7889098
doi: 10.1080/19420862.2020.1868078
Yoo D, Jaworski J, Matyska-Piekarska E, et al. FRI0128 A novel formulation of CT-P13 (infliximab biosimilar) for subcutaneous administration: 1-year results from a part 1 of phase I/III randomized controlled trial in patients with active rheumatoid arthritis. Ann Rheum Dis. 2019;78(Suppl_2):733.
Westhovens R, Yoo DH, Jaworski J, et al. THU0191 Novel formulation of CT-P13 for subcutaneous administration in patients with rheumatoid arthritis: initial results from a phase I/III randomised controlled trial. Ann Rheum Dis. 2018;77(Suppl_2):315.
European Medicines Agency. Remsima: assessment report on extension(s) of marketing authorisation. 2019. https://www.ema.europa.eu/en/documents/assessment-report/remsima-epar-public-assessment-report_en.pdf . Accessed 11 Apr 2022.
Reinisch W, Jang BI, Borzan V, et al. DOP62 A novel formulation of CT-P13 (infliximab biosimilar) for subcutaneous administration: 1-year result from a phase I open-label randomised controlled trial in patients with active Crohn’s disease. J Crohns Colitis. 2019;13(Suppl. 1):S066–7.
doi: 10.1093/ecco-jcc/jjy222.096
Ye BD, Jang BI, Borzan V, et al. Tu1715: a novel formulation of CT-P13 (infliximab biosimilar) for subcutaneous administration: 1-year result from a phase I open-label randomized controlled trial in patients with active Crohn’s disease. Gastroenterology. 2019;156(6):S-1096.
doi: 10.1016/S0016-5085(19)39701-X
Schreiber S, D'Haens G, Cummings F, et al. Switching from intravenous to subcutaneous infliximab in patients with active inflammatory bowel disease: post-hoc analysis of pre/post switch outcomes from a multicentre, randomised controlled pivotal trial [abstract and poster P0472, presented at UEG Week 2021]. 2021. https://programme.ueg.eu/week2021/#/details/presentations/1351 . Accessed 11 Apr 2022.
Hanzel J, Bukkems LH, Gecse KB, et al. Population pharmacokinetics of subcutaneous infliximab CT-P13 in Crohn’s disease and ulcerative colitis. Aliment Pharmacol Ther. 2021;54(10):1309–19.
pubmed: 34559426
doi: 10.1111/apt.16609
Zhu YW, Pendley C, Sisco D, et al. Pharmacokinetics and pharmacodynamics of infliximab, an anti-tumor necrosis factor-alpha monoclonal antibody, following single subcutaneous administrations in rheumatoid arthritis patients. Clin Pharmacol Ther. 2005;77(2):P43.
doi: 10.1016/j.clpt.2004.12.056
Combe B, Allanore Y, Alten R, et al. Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials. Arthritis Res Ther. 2021;23(1):119.
pubmed: 33863352
pmcid: 8051052
doi: 10.1186/s13075-021-02487-x
Yoo D-H, Westhovens R, Ben-Horin S, et al. Development of a subcutaneous formulation of CT-P13 (infliximab): maintenance subcutaneous administration may elicit lower immunogenicity compared to intravenous treatment [abstract 2514]. Arthritis Rheumatol. 2018;70(Suppl. 10). https://acrabstracts.org/abstract/development-of-a-subcutaneous-formulation-of-ct-p13-infliximab-maintenance-subcutaneous-administration-may-elicit-lower-immunogenicity-compared-to-intravenous-treatment/ . Accessed 21 May 2022.
Heald A, Bramham-Jones S, Davies M. Comparing cost of intravenous infusion and subcutaneous biologics in COVID-19 pandemic care pathways for rheumatoid arthritis and inflammatory bowel disease: a brief UK stakeholder survey. Int J Clin Pract. 2021;75(9): e14341.
pubmed: 33963659
doi: 10.1111/ijcp.14341
D’Amico F, Solitano V, Aletaha D, et al. Biobetters in patients with immune-mediated inflammatory disorders: an international Delphi consensus. Autoimmun Rev. 2021;20(7):102849.
pubmed: 33974946
doi: 10.1016/j.autrev.2021.102849
Agboton C, Salameh J. Biosimilars in chronic inflammatory diseases: facts and remaining questions 5 years after their introduction in Europe. Expert Opin Biol Ther. 2022;22(2):157–237.
pubmed: 34338115
doi: 10.1080/14712598.2021.1963435
Joachim R. Subcutaneous infliximab in the U.S.: defining CT-P13 SC's competitive edge. 2021. https://www.biosimilardevelopment.com/doc/subcutaneous-infliximab-in-the-u-s-defining-ct-p-sc-s-competitive-edge-0001 . Accessed 11 Apr 2022.
ClinicalTrials.gov. CT-P13 (infliximab) subcutaneous administration in patients with moderately to severely active Crohn's disease (NCT03945019). 2021. https://clinicaltrials.gov/ct2/show/NCT03945019 . Accessed 11 Apr 2022.
ClinicalTrials.gov. CT-P13 (infliximab) subcutaneous administration in patients with moderately to severely active ulcerative colitis (NCT04205643). 2021. https://clinicaltrials.gov/ct2/show/NCT04205643 . Accessed 11 Apr 2022.
Bittner B, Richter W, Schmidt J. Subcutaneous administration of biotherapeutics: an overview of current challenges and opportunities. BioDrugs. 2018;32(5):425–40.
pubmed: 30043229
pmcid: 6182494
doi: 10.1007/s40259-018-0295-0
Kariburyo MF, Xie L, Teeple A, et al. Predicting pre-emptive discussions of biologic treatment: results from an openness and preference survey of inflammatory bowel disease patients and their prescribers. Adv Ther. 2017;34(6):1398–410.
pubmed: 28484953
pmcid: 5487867
doi: 10.1007/s12325-017-0545-4
Russell AS, Gulliver WP, Irvine EJ, et al. Quality of life in patients with immune-mediated inflammatory diseases. J Rheumatol. 2011;88:7–19.
Spierings J, Sloeserwij A, Vianen ME, et al. Health-related quality of life in patients with immune mediated inflammatory diseases: a cross-sectional, multidisciplinary study. Clin Immunol. 2020;214:108392.
pubmed: 32224157
doi: 10.1016/j.clim.2020.108392
Eaton S. Delivering person-centred care in long-term conditions. Future Hosp J. 2016;3(2):128–31.
pubmed: 31098204
pmcid: 6465836
doi: 10.7861/futurehosp.3-2-128
Sumpton D, Oliffe M, Kane B, et al. Patients’ perspectives on shared decision-making about medications in psoriatic arthritis: an interview study. Arthritis Care Res (Hoboken). 2021. https://doi.org/10.1002/acr.24748 .
doi: 10.1002/acr.24748